FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.
Natural killer/T-cell lymphoma (NKTCL) is a malignancy with a poor prognosis. The Smoothened (Smo) protein is implicated in NKTCL growth. This study employed lentiviral vector-mediated Smo RNA interference (LV- Smo -RNAi) to silence the Smo gene in the human NKTCL cell line SNT8. Fluorescence microscopy, qRT-PCR, and Western blot verified the reduction of Smo mRNA and protein levels. The CCK-8 assay showed that Smo silencing inhibited cell proliferation. Flow cytometry with annexin V-PE/7-AAD double staining indicated an increased apoptosis rate. Moreover, the expression of GLI family zinc finger 1 (Gli1) and programmed death-ligand 1 (PD-L1) was downregulated. In vivo, xenotransplantation experiments demonstrated that Smo silencing led to slower tumor growth with reduced tumor volume and weight. Overall, Smo gene silencing holds great potential as a novel molecular-targeted therapy approach for NKTCL by effectively suppressing cell proliferation and promoting apoptosis.